Intra-arterial cold saline, minocycline, and magnesium for Ischemic Stroke

Phase-Based Progress Estimates
North Shore University Hospital, Manhasset, NYIschemic StrokeIntra-arterial cold saline, minocycline, and magnesium - Drug
18 - 90
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether it is safe to give patients a cocktail of neuroprotective drugs immediately after they have a stroke, in order to try to improve long-term outcomes.

Eligible Conditions
  • Ischemic Stroke

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: within 24 hours of treatment

24 hours after procedure
Infarct volume
90 days after intervention
Functional outcome
Hour 24
Intracranial hemorrhage
Hour 72
Presence of serious adverse event

Trial Safety

Safety Progress

1 of 3

Side Effects for

20%Peripheral Neuropathy
This histogram enumerates side effects from a completed 2017 Phase 2 trial (NCT01746043) in the Armodafinil+Minocycline ARM group. Side effects include: Peripheral Neuropathy with 20%.

Trial Design

1 Treatment Group

Intra-arterial neuroprotective substances
1 of 1

Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: Intra-arterial cold saline, minocycline, and magnesium · No Placebo Group · Phase 1

Intra-arterial neuroprotective substances
Experimental Group · 1 Intervention: Intra-arterial cold saline, minocycline, and magnesium · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: within 24 hours of treatment

Who is running the clinical trial?

Northwell HealthLead Sponsor
426 Previous Clinical Trials
462,399 Total Patients Enrolled
1 Trials studying Ischemic Stroke
53 Patients Enrolled for Ischemic Stroke
Thomas W Link, MD, MSPrincipal InvestigatorNorthwell Health

Eligibility Criteria

Age 18 - 90 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: